Reply to correspondence on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study” Eileen Laurel Yoon, Dae Won Jun Clinical and Molecular Hepatology.2024; 30(4): 1033. CrossRef
Background/Aims Metabolic dysfunction-associated steatotic liver disease (MASLD) was recently proposed as an alternative disease concept to nonalcoholic fatty liver disease (NAFLD). We aimed to investigate the prognosis of patients with biopsy-confirmed MASLD using data from a multicenter study.
Methods This was a sub-analysis of the Clinical Outcome Nonalcoholic Fatty Liver Disease (CLIONE) study that included 1,398 patients with NAFLD. Liver biopsy specimens were pathologically diagnosed and histologically scored using the NASH Clinical Research Network system, the FLIP algorithm, and the SAF score. Patients who met at least one cardiometabolic criterion were diagnosed with MASLD.
Result s: Approximately 99% of cases (n=1,381) were classified as MASLD. Patients with no cardiometabolic risk (n=17) had a significantly lower BMI than patients with MASLD (20.9 kg/m2 vs. 28.0 kg/m2, P<0.001), in addition to significantly lower levels of inflammation, ballooning, NAFLD activity score, and fibrosis stage based on liver histology. These 17 patients had a median follow-up of 5.9 years, equivalent to 115 person-years, with no deaths, liver-related events, cardiovascular events, or extrahepatic cancers. The results showed that the prognosis for pure MASLD was similar to that for the original CLIONE cohort, with 47 deaths and one patient who underwent orthotopic liver transplantation. The leading cause of death was extrahepatic cancer (n=10), while the leading causes of liver-related death were liver failure (n=9), hepatocellular carcinoma (n=8), and cholangiocarcinoma (n=4).
Conclusions Approximately 99% of NAFLD cases were considered MASLD based on the 2023 liver disease nomenclature. The NAFLD-only group, which is not encompassed by MASLD, had a relatively mild histopathologic severity and a favorable prognosis. Consequently, the prognosis of MASLD is similar to that previously reported for NAFLD.
Citations
Citations to this article as recorded by
The Bubble-Destruction Curve Obtained Using Contrast-Enhanced Ultrasound is Useful for Assessing Liver Fibrosis and Identifying At-risk MASH in Patients With MASLD Noritaka Wakui, Yu Ogino, Naohisa Kamiyama, Takuma Oguri, Tomoya Uchimura, Takahide Kudo, Kenichi Maruyama, Hideki Nagumo, Naoyuki Yoshimine, Kunihide Mouri, Kojiro Kobayashi, Takanori Mukozu, Teppei Matsui, Hidenari Nagai, Yoshinori Igarashi, Takahisa Ma Ultrasound in Medicine & Biology.2026; 52(1): 237. CrossRef
Ethnic disparities in metabolic dysfunction-associated steatotic liver disease and clinical outcomes Yusuke Miyatani, Aoi Ogawa, Tomoki Sempokuya, Chuong Tran, Davis James, Todd Seto, Cecilia Shikuma, Scott K. Kuwada Frontiers in Endocrinology.2026;[Epub] CrossRef
Measures of comorbid cardiometabolic burden and cardiovascular disease risk in people with MRI-confirmed steatotic liver disease: a prospective cohort study Qi Feng, Pinelopi Manousou, Chioma N. Izzi-Engbeaya, Mark Woodward Cardiovascular Diabetology.2026;[Epub] CrossRef
Multicenter Prospective Cohort Study on Clinical Outcomes and Fibrosis Patterns in Biopsy-Proven Steatotic Liver Disease Subtypes Gi-Ae Kim, Heejoon Jang, Moon Young Kim, Jeong Hwan Park, Jung Gil Park, Eun-Young Cho, Jae Yoon Jeong, Seogsong Jeong, Seul Ki Han, Heesu Kwon, Youngae Jung, Geum-Sook Hwang, Yu Rim Lee, Soo Young Park, Sang Gyune Kim, Won Kim Gastroenterology.2026;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases Yiyuan Xiao, Sihua Xu, Wenyan Hu, Jiapeng Huang, Deke Jiang, Rong Na, Zhaoqing Yin, Jingjing Zhang, Haitao Chen Annals of Hepatology.2025; 30(1): 101750. CrossRef
Alcohol Intake and Cardiometabolic Risk Factors Are Independently Associated With a Higher AST/Platelet Ratio Index in Obese Males Hideki Fujii, Yoshihiro Kamada, Yuichiro Suzuki, Koji Sawada, Miwa Tatsuta, Tatsuji Maeshiro, Hiroshi Tobita, Tsubasa Tsutsumi, Takemi Akahane, Chitomi Hasebe, Miwa Kawanaka, Takaomi Kessoku, Yuichiro Eguchi, Hayashi Syokita, Atsushi Nakajima, Tomoari Kam Liver International Communications.2025;[Epub] CrossRef
Cardiometabolic dysfunction burden and mortality outcomes in metabolic dysfunction-associated steatotic liver disease Ying Wen, Yu Min, Yi Lei, Zhigong Wei, Sophia Eugenia Martínez-Vázquez PLOS One.2025; 20(7): e0327772. CrossRef
The PNPLA3 I148M variant is associated with immune cell infiltration and advanced fibrosis in MASLD: a prospective genotype–phenotype study Jaejun Lee, Jung Hoon Cha, Hee Sun Cho, Keungmo Yang, Hyun Yang, Heechul Nam, Mi Young Byun, Seok Keun Cho, Jinsung Park, Hyuk Wan Ko, Seong Wook Yang, Pil Soo Sung, Si Hyun Bae Journal of Gastroenterology.2025; 60(10): 1284. CrossRef
Effects of laser acupuncture (stress-free therapy) on blood liver function indicators Yoshihiro Kamada, Takunori Sato, Takaomi Kessoku, Yoshio Sumida, Masafumi Ono, Kenji Ryotokuji Laser Therapy.2025;[Epub] CrossRef
Steatotic Liver Disease: A Key Related Risk Factor in the Emergence of Metabolic Syndrome‐Related Disorders Yoshihiro Kamada, Makoto Fujii, Hitoshi Nishizawa, Shiro Fukuda, Makoto Yamada, Iichiro Shimomura, Eiji Miyoshi Hepatology Research.2025;[Epub] CrossRef
Concept, Diagnosis, and Treatment in Steatotic Liver Disease (SLD) Yoshio Sumida, Takaomi Kessoku, Hirotoshi Ebinuma Health Evaluation and Promotion.2025; 52(6): 794. CrossRef
COMBINED DISORDER: CURRENT STATUS OF METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE IN PATIENTS WITH HYPOTHYROIDISM AND PROSPECTS FOR PATIENT PATHWAY IMPLEMENTATION Valentyna Psarova, Anastasiia Cherkashyna Eastern Ukrainian Medical Journal.2025; 13(3): 593. CrossRef
Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences Joo Hyun Oh, Dae Won Jun Clinical and Molecular Hepatology.2024; 30(2): 168. CrossRef
Correspondence on Letter regarding “Prognosis of biopsy-confirmed MASLD: A sub-analysis of the CLIONE study” Hideki Fujii, Michihiro Iwaki, Yoshihiro Kamada Clinical and Molecular Hepatology.2024; 30(2): 281. CrossRef
Usefulness of health checkup‐based indices in identifying metabolic dysfunction‐associated steatotic liver disease Takao Miwa, Satoko Tajirika, Nanako Imamura, Miho Adachi, Ryo Horita, Tatsunori Hanai, Cheng Han Ng, Mohammad Shadab Siddiqui, Taku Fukao, Masahito Shimizu, Mayumi Yamamoto JGH Open.2024;[Epub] CrossRef
Association between nonalcholic fatty liver disease and pancreatic cancer: Epidemiology, mechanisms, and antidiabetic medication Takahiko Sakaue, Hiroya Terabe, Hidetoshi Takedatsu, Takumi Kawaguchi Hepatology Research.2024; 54(8): 729. CrossRef
Reply to correspondence on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study” Eileen Laurel Yoon, Dae Won Jun Clinical and Molecular Hepatology.2024; 30(4): 1033. CrossRef
Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease: Letter to the editor on “Prognosis of biopsy-confirmed metabolic dysfun Yixuan Zhu, Xiaoyan Ma, Wenjing Ni, Yee Hui Yeo, Junping Shi, Jie Li Clinical and Molecular Hepatology.2024; 30(4): 974. CrossRef
Sequential Diagnostic Approach Using FIB-4 and ELF for Predicting Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Yeo-Wool Kang, Yang-Hyun Baek, Sang-Yi Moon Diagnostics.2024; 14(22): 2517. CrossRef
Combi-Elastography versus Transient Elastography for Assessing the Histological Severity of Metabolic Dysfunction-Associated Steatotic Liver Disease Yun Kyu Lee, Dong Hyeon Lee, Sae Kyung Joo, Heejoon Jang, Young Ho So, Siwon Jang, Dong Ho Lee, Jeong Hwan Park, Mee Soo Chang, Won Kim Gut and Liver.2024; 18(6): 1048. CrossRef
Liver fibrosis reflects tissue scarring in the liver due to the accumulation of excessive extracellular matrix in response to chronically persistent liver injury. Hepatocyte cell death can trigger capillarization of liver sinusoidal endothelial cells, stimulation of immune cells including macrophages and Kupffer cells, and activation of hepatic stellate cells (HSCs), resulting in progression of liver fibrosis. Liver cirrhosis is the terminal state of liver fibrosis and is associated with severe complications, such as liver failure, portal hypertension, and liver cancer. Nevertheless, effective therapy for cirrhosis has not yet been established, and liver transplantation is the only radical treatment for severe cases. Studies investigating HSC activation and regulation of collagen production in the liver have made breakthroughs in recent decades that have advanced the knowledge regarding liver fibrosis pathophysiology. In this review, we summarize molecular mechanisms of liver fibrosis and discuss the development of novel anti-fibrotic therapies.
Citations
Citations to this article as recorded by
Roumudan decoction attenuates hepatic fibrosis by suppressing the Warburg effect via inhibiting key glycolytic proteins Meng Pan, Huanyu Li, Hao Guo, Shiting Luo, Jianxuan Yao, Mingxin Zhang, Yang Luo, Xiaoyan Shi Journal of Ethnopharmacology.2026; 356: 120862. CrossRef
Advanced strategies based on nanomedicine for Liver fibrosis treatment Lu Zhang, Tingting Liu, Huan Shen, Boheng Liu, Yun Mei, Yang Liu, Shuo Chen, Xingcong Ma, Chenyang He, Tinghua Hu, Bin Li, Gang Cao, Shuo Yu International Journal of Pharmaceutics.2026; 688: 126437. CrossRef
Salvianolic acid B targets MST1/2-YAP axis to drive phospho-Smad3L/C conversion against hepatocarcinogenesis Wenjing Xu, Yanyan Xu, Shuchen Han, Yuqi Dang, Changfeng Xue, Jingqi Zhou, Shufang He, Yongfang Gong, Yan Yang Phytomedicine.2026; 150: 157655. CrossRef
Modulating MiR-350/Akt/mTOR/beclin1 signaling by nitazoxanide ameliorates bleomycin-induced pulmonary fibrosis in a wistar rat model Eman M. Elbaz, Yara Shawky, Amina A.S. Abdel Rahman, Maha Abdelmonem Life Sciences.2026; 386: 124166. CrossRef
Immune System and Hepatic Stellate Cells’ Crosstalk in Liver Fibrosis: Pathways and Therapeutic Potential Wahyu Widowati, Adilah Hafizha Nur Sabrina, Annisa Firdaus Sutendi, Fadhilah Haifa Zahiroh, Aris Muhamad Nurjamil, Teresa Liliana Wargasetia, Ita Margaretha Nainggolan, Rizal Azis, Elham Rismani, Massoud Vosough, Poorani Gurumallesh Prabu Journal of Immunology Research.2026;[Epub] CrossRef
The Fibrosis-5 Index Predicts Major Adverse Cardiovascular Events in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention Senjiang Chen, Bouwei Zhu, Zan Luo, Yinchao Wang, Qingqing Hu, Liang Zhou Angiology.2025; 76(8): 734. CrossRef
Hepatic antifibrotic effects of bezafibrate in vitro and in vivo models of liver fibrosis Camille Kirinus Reghelin, Matheus Scherer Bastos, Bruno de Souza Basso, Bruna Pasqualotto Costa, Arieli Cruz de Sousa, Bianca Andrade Martha, Géssica Luana Antunes, Marcella Tornquist Nassr, Maria Claudia Rosa Garcia, Lucas Strassburger Matzenbacher, Vito Food and Chemical Toxicology.2025; 200: 115351. CrossRef
Multiomics Analysis and Machine Learning-based Identification of Molecular Signatures for Diagnostic Classification in Liver Disease Types Along the Microbiota-gut-liver Axis Betul Comertpay, Esra Gov Journal of Clinical and Experimental Hepatology.2025; 15(5): 102552. CrossRef
Challenges of in vitro modelling of liver fibrosis Patricia Ros-Tarraga, Estela Villanueva-Badenas, Estela Sanchez-Gonzalez, Gloria Gallego-Ferrer, M. Teresa Donato, Laia Tolosa Frontiers in Cell and Developmental Biology.2025;[Epub] CrossRef
Phosphocreatine alleviates liver fibrosis in diabetic mice by targeting TGF-β/Smad and α-SMA pathways Fu Han Wang, Eskandar Qaed, Waleed Aldahmash, Mueataz A. Mahyoub, Dalal Sanad Al-Mutairi, Zeyao Tang, Marwan almoiliqy Tissue and Cell.2025; 96: 103013. CrossRef
Real-World Experience of Home Continuous Terlipressin Infusion for Complications of Portal Hypertension Brooke Chapman, Marie Sinclair, Avik Majumdar, Catherine Yu, James Widdop, Rudolf Hoermann, Kate Collins, Ryma Terbah, Katrina Tan, Adam Testro American Journal of Gastroenterology.2025;[Epub] CrossRef
Co-Assembled Nanoparticles Comprising Sorafenib and Hederagenin Derivative for Enhanced Anti-Hepatic Fibrosis Activity Mingjun Lu, Ziqi Dai, Yixuan Lin, Changsheng Sun, Shuo Li, Zhuoqian Guo, Yongji Liu, Xiaobi Liu, Shanlan Li, Runping Liu, Bing Xu, Haimin Lei International Journal of Nanomedicine.2025; Volume 20: 9135. CrossRef
Global, Regional, and National Burden of Chronic Hepatitis B-Related Cirrhosis From 1990 to 2021 and Projections to 2050: A Finding From the Global Burden of Disease Study 2021 Jinyan Sun, Jin Guo Clinical and Translational Gastroenterology.2025; 16(10): e00890. CrossRef
Discovery of novel anti-fibrotics through phenotypic screening Alice R. Lapthorn, Sophie L. Harding-Fox, Kieran M. Feltham, Marcus M. Ilg, Selim Cellek Drug Discovery Today.2025; 30(9): 104450. CrossRef
Shining light on liquid–liquid phase separation in chronic liver disease Ming-Hui Li, Yang Yang, Qi-Qi Dong, Wen-Jie Sun, Hui Tao, Jing-Jing Yang Drug Discovery Today.2025; 30(10): 104464. CrossRef
Tetramethylpyrazine improves the structure and function of mitochondrial-associated endoplasmic reticulum membrane and liver fibrosis Kaihong Xie, Jianzhi Wu, Liping Gong, Wenqing Qin, Zixuan Huo, Yinhao Zhang, Jiaorong Qu, Runping Liu, Jianan Li, Jianhang Lan, Yufei Li, Ranyi Luo, Xiaojiaoyang Li Journal of Advanced Research.2025;[Epub] CrossRef
Design, Synthesis, and Evaluation of Antifibrotic Activity of Nonsteroidal VDR Agonists Featuring 1,6-Naphthol as a CD-Ring Surrogate Yi Gao, Yue Wu, Chun Guan, Nuo Cheng, Yu Tong, Cong Wang, Can Zhang Journal of Medicinal Chemistry.2025; 68(19): 20561. CrossRef
Sublingual Dripping Pill Formulation of Ganoderma amboinense Fruiting Body Extract Attenuates CCl4-Induced Liver Fibrosis via Multi-Pathway Regulation Chin-Feng Liu, Chong-Ming Pan, Chun-Lin Lee Current Issues in Molecular Biology.2025; 47(9): 697. CrossRef
Resveratrol ameliorates liver fibrosis by inhibiting ATF4 to regulate glutamine metabolism in hepatic stellate cells Huiya Ying, Yixiao Wang, Dandan Zhu, Jun Xu, Xiangting Zhang, Hong Pan, Yuan Zeng, Xiao Wu, Weimin Cai, Ruoru Zhou, Ziqiang Xia, Fujun Yu Archives of Pharmacal Research.2025; 48(11-12): 1420. CrossRef
Hepatic Fibrosis and Liver Cancer Aina Anton, Scott L. Friedman, Bruno Cogliati Seminars in Liver Disease.2025;[Epub] CrossRef
Recent Progresses on Pathophysiology, Diagnosis, Therapeutic Modalities,
and Management of Non-alcoholic Fatty Liver Disorder Mahdi Barazesh, Sajad Jalili, Morteza Akhzari, Fouzieyeh Faraji, Ebrahim Khorramdin Current Drug Therapy.2024; 19(1): 20. CrossRef
An RORα agonist, ODH-08, inhibits fibrogenic activation of hepatic stellate cells via suppression of SMAD3 Haena Choi, Daehyun Oh, Hyeon-Ji Kim, Melody Chambugong, Mi-hyun Kim, Mi-Ock Lee, Hyeung-geun Park Life Sciences.2024; 340: 122443. CrossRef
TNFRSF12A mRNA Expression and Distribution of TNFRSF12A+ Cells in the Rate Liver during Thioacetamide-Induced Fibrogenesis E. I. Lebedeva, A. T. Shchastniy, A. S. Babenka Biology Bulletin.2024; 51(1): 11. CrossRef
RNA-seq combined network pharmacology reveals that Fu-Gan-Wan (FGW) inhibits liver fibrosis via NF-κB/CCL2/CCR2 and lipid peroxidation via Nrf2/HMOX1 signaling pathway Hanlin Shi, Xiaohong Duan, Jingcheng Dong, Yanyan Tao, Yang Lei Journal of Ethnopharmacology.2024; 326: 117963. CrossRef
Novel protein C6ORF120 promotes liver fibrosis by activating hepatic stellate cells through the PI3K/Akt/mTOR pathway Xin Wang, Hui Liu, Yuqi Wang, Peng Wang, Yunyun Yi, Yingying Lin, Xin Li Journal of Gastroenterology and Hepatology.2024; 39(7): 1422. CrossRef
The current landscape of antifibrotic therapy across different organs: A systematic approach Isabel Fuster-Martínez, Sara Calatayud Pharmacological Research.2024; 205: 107245. CrossRef
TNFRSF12A mRNA Expression and distribution of TNFRSF12A+ cells in rat liver during thioacetamide-induced fibrogenesis Elena I. Lebedeva, Anatoly T. Shchastniy, Andrei S. Babenka Известия Российской академии наук. Серия биологическая.2024; (1): 14. CrossRef
LOXL2 in non‐alcoholic Steatohepatitis (NASH): Insights into fibrosis pathogenesis and therapeutic potential Joys Rachel Immanuel, Rajnish Kumar, Ashish Kumar Agrahari, Shailendra Asthana Liver International Communications.2024;[Epub] CrossRef
Two-dimensional vascularized liver organoid on extracellular matrix with defined stiffness for modeling fibrotic and normal tissues Lei Ma, Lin Yin, Hai Zhu, Jing Li, Dong Wang Journal of Tissue Engineering.2024;[Epub] CrossRef
Phytotherapeutic approach to enhance the hepatoprotective activity of some edible plants: Molecular docking and nanoformulation Khaled A. Nematallah, Amgad Albohy, Noha Swilam Journal of Functional Foods.2024; 122: 106471. CrossRef
Advances in the understanding of the role and mechanism of action of PFKFB3‑mediated glycolysis in liver fibrosis (Review) Qian Liu, Jiajia Li, Xin Li, Li Zhang, Shun Yao, Yongfeng Wang, Biguang Tuo, Hai Jin International Journal of Molecular Medicine.2024;[Epub] CrossRef
Nitazoxanide mitigates methotrexate hepatotoxicity in rats: role in inhibiting apoptosis and regulating endoplasmic reticulum stress Nevertyty Mohamed Mahmoud, Shimaa M. Elshazly, Fatma El-shaarawy, Sawsan A. Zaitone, Afaf A. Aldahish, Gehan A. Ahmed, Manal S. Fawzy, Sheka Yagub Aloyouni, Sally Y. Abed, Tahani Saeedi, Shaimaa S. El-Sayed Frontiers in Pharmacology.2024;[Epub] CrossRef
Diagnostic Efficacy of Serum Asialo α1-Acid Glycoprotein Levels for Advanced Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Compared to That in Healthy Subjects: A Prospective Study Yoonseok Lee, Seryun Bae, Ji Hoon Kim, Minjung Kwak, So Yeon Jeon, Taehyung Kim, Sun Young Yim, Young-Sun Lee, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun Journal of Clinical Medicine.2023; 12(2): 712. CrossRef
Association between Cardiovascular Disease and Liver Disease, from a Clinically Pragmatic Perspective as a Cardiologist Mitsutaka Nakashima, Kazufumi Nakamura, Takahiro Nishihara, Keishi Ichikawa, Rie Nakayama, Yoichi Takaya, Norihisa Toh, Satoshi Akagi, Toru Miyoshi, Teiji Akagi, Hiroshi Ito Nutrients.2023; 15(3): 748. CrossRef
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials Jihyun An, Joo Hyun Sohn Clinical and Molecular Hepatology.2023; 29(Suppl): S268. CrossRef
Immune microenvironment changes of liver cirrhosis: emerging role of mesenchymal stromal cells Qiuyun Yi, Jinxian Yang, Ying Wu, Ying Wang, Qiqi Cao, Wen Wen Frontiers in Immunology.2023;[Epub] CrossRef
Hydronidone ameliorates liver fibrosis by inhibiting activation of hepatic stellate cells via Smad7‐mediated degradation of TGFβRI Xianjun Xu, Yuecheng Guo, Xin Luo, Zhenyang Shen, Zhongshang Sun, Bo Shen, Cui Zhou, Junjun Wang, Jingyi Lu, Qingqing Zhang, Yanping Ye, Ying Luo, Ying Qu, Xiaobo Cai, Hui Dong, Lungen Lu Liver International.2023; 43(11): 2523. CrossRef
Hepatoprotective Effect of Medicine Food Homology Flower Saffron against CCl4-Induced Liver Fibrosis in Mice via the Akt/HIF-1α/VEGF Signaling Pathway Huajuan Jiang, Xulong Huang, Jiaxin Wang, Yongfeng Zhou, Chaoxiang Ren, Tao Zhou, Jin Pei Molecules.2023; 28(21): 7238. CrossRef
Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches Omima S. Mohammed, Hany G. Attia, Bassim M. S. A. Mohamed, Marawan A. Elbaset, Hany M. Fayed Journal of Pharmacy & Pharmaceutical Sciences.2023;[Epub] CrossRef
A Unique Immune-Related Gene Signature Represents Advanced Liver Fibrosis and Reveals Potential Therapeutic Targets Pil-Soo Sung, Chang-Min Kim, Jung-Hoon Cha, Jin-Young Park, Yun-Suk Yu, Hee-Jung Wang, Jin-Kyeoung Kim, Si-Hyun Bae Biomedicines.2022; 10(1): 180. CrossRef
Stanniocalcin 1 is a serum biomarker and potential therapeutic target for HBV‐associated liver fibrosis Kristy Kwan‐Shuen Chan, Tsz‐Chun Hon, Kwan‐Yung Au, Hiu‐Lam Choi, Danny Ka‐Ho Wong, Albert Chi‐Yan Chan, Man‐Fung Yuen, Ching‐Lung Lai, Regina Cheuk‐Lam Lo The Journal of Pathology.2022; 257(2): 227. CrossRef
The Role of Macrophages in Liver Fibrosis: New Therapeutic Opportunities Eleonora Binatti, Alessio Gerussi, Donatella Barisani, Pietro Invernizzi International Journal of Molecular Sciences.2022; 23(12): 6649. CrossRef
Treatment of Liver Fibrosis: A 20-Year Bibliometric and Knowledge-Map Analysis Yun-Kai Dai, Zhi-Min Zhao, Chenghai Liu Frontiers in Pharmacology.2022;[Epub] CrossRef
The emerging roles of extracellular vesicles as intercellular messengers in liver physiology and pathology Youngseok Lee, Jong-Hoon Kim Clinical and Molecular Hepatology.2022; 28(4): 706. CrossRef
Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach Michael H. Le, Yee Hui Yeo, Biyao Zou, Scott Barnet, Linda Henry, Ramsey Cheung, Mindie H. Nguyen Clinical and Molecular Hepatology.2022; 28(4): 841. CrossRef
Multiplexed Digital Spatial Protein Profiling Reveals Distinct Phenotypes of Mononuclear Phagocytes in Livers with Advanced Fibrosis Jaejun Lee, Chang Min Kim, Jung Hoon Cha, Jin Young Park, Yun Suk Yu, Hee Jung Wang, Pil Soo Sung, Eun Sun Jung, Si Hyun Bae Cells.2022; 11(21): 3387. CrossRef
Hepatic HRC induces hepatocyte pyroptosis and HSCs activation via NLRP3/caspase-1 pathway Jingwen Wu, Mingyu Zhang, Suhong Xia, Ping Han, Kai Zhao, Kaixin Peng, Wangdong Zhou, Dean Tian, Jiazhi Liao, Jingmei Liu Journal of Molecular Medicine.2022; 100(12): 1787. CrossRef
Myofibroblast specific targeting approaches to improve fibrosis treatment Elfa Beaven, Raj Kumar, Himanshu N. Bhatt, Stephanie V. Esquivel, Md Nurunnabi Chemical Communications.2022; 58(98): 13556. CrossRef
Multiplexed Digital Spatial Protein Profiling Reveals a Unique Protein Signature for Advanced Liver Fibrosis Jaejun Lee, Chang Min Kim, Jung Hoon Cha, Jin Young Park, Yun Suk Yu, Hee Jung Wang, Pil Soo Sung, Eun Sun Jung, Si Hyun Bae SSRN Electronic Journal .2022;[Epub] CrossRef
Protective Effect of Oligonol on Dimethylnitrosamine-Induced Liver Fibrosis in Rats via the JNK/NF-κB and PI3K/Akt/Nrf2 Signaling Pathways Changyong Lee, Jeonghyeon Bak, Sik Yoon, Jeon-Ok Moon Antioxidants.2021; 10(3): 366. CrossRef
First
Prev
